On January 17th, the much-anticipated inaugural Huashan Awards for Innovative Drugs were officially unveiled in Shanghai. The ceremony brought together distinguished guests including Mr. Qirui Chen, Co-initiator of the Huashan Awards and Founder and Chairman of MedJ; Dr. Zengjiang Cheng, Co-initiator of the Huashan Awards and Founder and Chairman of TongXieYi; Professor Kaixian Chen, Deputy Chief Scientist of the National Major New Drug Innovation Program and Researcher at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences; Mr. Houjia Liu, Director of the Shanghai Center for Biotechnology and Pharmaceutical Industry Promotion; Dr. Chunlin Jin, Member of the Huashan Awards Management Committee and Director of the Shanghai Health and Development Research Center; Professor Shanlian Hu from the School of Public Health at Fudan University; Dr. Yaning Wang, Co-Chair of the Huashan Awards Management Committee, former Director of the FDA Division of Clinical Quantitative Pharmacology, and Founder, Chairman and CEO of Ruining Kang Biopharmaceutical; Dr. Ruyi He, President of the Shanghai Global Health Innovation Institute; Dr. Yiman Zheng, Member of the Huashan Awards Management Committee and Vice President of Medical Affairs at Merck Sharp & Dohme (MSD) China; Mr. Tan Hong, Huashan Awards Review Expert and Managing Director of Legend Capital; Mr. Rui Zhou, Huashan Awards Review Expert, former inaugural fund manager of China Universal Healthcare Equity Fund, Executive Director and General Manager of Shanghai Lanshi Private Equity Fund, and Chairman and General Manager of Shanghai Dingxin Gene Technology; Ms. Jie Chen, Co-founder, General Manager and Chief Medical Officer of MedJ; as well as more than 300 experts, scholars, and founders and executives from the fields of innovative drug research, clinical development, and investment.
Jointly initiated by MedJ and TongXieYi, the Huashan Awards are grounded in professional judgment, international standards, public evaluation, and the identification of Chinese exemplars, with the goal of discovering value-based healthcare benchmarks in China’s innovative drug sector. With the vision of becoming the most influential innovative drug award in China, the Huashan Awards are committed to upholding scientific rigor, setting industry benchmarks, incentivizing original innovation, and supporting industrial upgrading. The Awards embrace future medicine, adhere to evidence-based medicine, promote value-based healthcare, and seek to amplify the power of role models through principled and fair evaluation.
The inaugural Huashan Awards presented five major awards, including three enterprise awards—Best Leading Innovative Pharmaceutical Enterprise Award, Best Growing Innovative Pharmaceutical Enterprise Award, and Best Potential Innovative Pharmaceutical Enterprise Award—and two drug awards—Best Clinical Value Medication Award and Best Technological Breakthrough Medication Award.

The 1st Huashan Award Trophy
The unveiling of the inaugural Huashan Awards marked the emergence of value-based healthcare benchmarks in China’s innovative drug industry.
Following evaluation by the Huashan Awards Expert Review Committee and Management Committee, four enterprises were honored with the Best Leading Innovative Pharmaceutical Enterprise Award, three enterprises received the Best Growing Innovative Pharmaceutical Enterprise Award, and three enterprises were awarded the Best Potential Innovative Pharmaceutical Enterprise Award. One medication received the Best Clinical Value Medication Award, and three medications were granted the Best Technological Breakthrough Medication Award.
Best Innovative Rising Biotech
Awardee (Company): Kelun-Biotech
Rationale for Award:
Kelun-Biotech is recognized for its TROP2-targeting ADC sacituzumab tirumotecan and its global Phase III clinical development in collaboration with MSD, demonstrating strong innovation capability and international competitiveness.
Awardee (Company): Biokin Pharmaceutical
Rationale for Award:
Biokin Pharmaceutical is honored for pioneering the world’s first ivonescimab-based bispecific ADC and securing a record-setting global partnership with Bristol Myers Squibb, highlighting its breakthrough innovation and global value.
Awardee (Company): Zelgen Biopharmaceuticals
Rationale for Award:
Zelgen Biopharmaceuticals is awarded for its highly differentiated pipeline potential and innovation strength, which received strong recognition beyond conventional quantitative evaluation.
Best Innovative Growing Biopharma
Awardee (Company): Innovent Biologics
Rationale for Award:
Innovent Biologics is recognized for building a balanced and diversified pipeline across oncology and chronic diseases, establishing itself as a core driver of China’s biopharmaceutical innovation ecosystem.
Awardee (Company): Akeso
Rationale for Award:
Akeso is honored for its pioneering PD-1/VEGF bispecific antibody ivonescimab, which has influenced global R&D trends and significantly enhanced the international visibility of China’s innovative drugs.
Awardee (Company): Allist Pharmaceuticals
Rationale for Award:
Allist Pharmaceuticals is awarded for the successful commercialization of its third-generation EGFR-TKI furmonertinib, demonstrating strong clinical value and sustained market growth.
Best Innovative Big Pharma
Awardee (Company): Eli Lilly and Company (China)
Rationale for Award:
Eli Lilly and Company (China) is recognized for its long-term commitment to China through substantial investment, innovation collaboration, and contribution to the local pharmaceutical ecosystem.
Awardee (Company): AstraZeneca (China)
Rationale for Award:
AstraZeneca (China) is honored for its leadership in localization, global R&D integration, and sustained contribution to advancing innovation and healthcare development in China.
Awardee (Company): BeiGene
Rationale for Award:
BeiGene is awarded for its Best-in-Class oncology innovation led by zanubrutinib and its successful global commercialization, positioning it as a China-born biopharmaceutical leader worldwide.
Awardee (Company): Hengrui Pharmaceuticals
Rationale for Award:
Hengrui Pharmaceuticals is recognized for its sustained high-level R&D investment and extensive Class 1 innovative drug approvals, setting a benchmark for innovation among Chinese pharmaceutical companies.
Best Breakthrough Medication
Awardee (Medication): Qfitlia (fitusiran sodium injection) — Sanofi
Rationale for Award:
Qfitlia is honored for introducing RNA interference technology into hemophilia treatment, establishing a transformative new therapeutic paradigm.
Awardee (Medication): Vyvgart (efgartigimod alfa injection) — Argenx / Zai Lab
Rationale for Award:
Vyvgart is recognized as the world’s first FcRn antagonist, pioneering a novel mechanism for autoimmune disease treatment with significant clinical impact.
Awardee (Medication): Sunvozertinib Tablets — Dizal Pharma
Rationale for Award:
Sunvozertinib is awarded for delivering a breakthrough targeted therapy for EGFR exon 20 insertion–mutant lung cancer, addressing a long-standing unmet medical need.
Best Clinical Value Medication
Awardee (Medication): Enhertu® (fam-trastuzumab deruxtecan-nxki) — Daiichi Sankyo / AstraZeneca China
Rationale for Award:
Enhertu® is recognized for redefining treatment paradigms for HER2-expressing cancers through its strong clinical efficacy, broad indications, and high real-world clinical value.
In addition to the Huashan Awards ceremony, the 2026 China Innovative Drug New Year Outlook Conference was held in the afternoon, featuring four roundtable discussions and multiple keynote speeches. Topics included AI-enabled drug discovery, alpha and beta strategies for innovative pharmaceutical companies in 2026, and the impact of new Chinese market policies on innovative drugs, offering participants a rich exchange of insights and perspectives.
As emphasized by speakers and panelists, driven by policy support, scientific foundations, market demand, and capital empowerment, China’s innovative drug industry has entered a new phase characterized by rapid advancement and simultaneous improvement in quality and efficiency. From original breakthroughs to global expansion, Chinese innovative drugs are entering a golden period of intensive value realization, supported by rising R&D capabilities, advancing commercialization strength, and accelerated internationalization.
Amid this competitive and transformative journey, MedJ will continue to uphold its principles of science, professionalism, and integrity, consistently advancing value-based healthcare, identifying benchmark innovations, and working alongside industry peers to support the sustainable and healthy development of China’s innovative drug sector as it moves toward global leadership.
As a witness to this historic endeavor, the Huashan Awards will continue to be held in future editions. We look forward to meeting again at the next Huashan Awards.